In Australia, Eurasia, Israel and USA
Suven Life Sciences announced that they secured patents in Australia, Eurasia, Israel and USA to their New Chemical Entities for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2032, 2030, 2031 and 2032 respectively.Powered by Capital Market - Live News